About the Company

ADMA Biologics (NasdaqCM: ADMA) is a late stage biopharmaceutical company that develops and intends to market plasma derived therapeutics targeted to immune compromised patients against certain infectious diseases. ADMA Biologics lead product candidate, RI-002 has completed all patient dosing in its Phase III trial and while patient follow up continues, there have been no reported serious adverse events attributable to RI-002 to date. RI-002 is a specialty plasma derived immune globulin with standardized, high-levels of RSV antibodies for the treatment of primary immune deficiency disease (PIDD). Primary endpoint, Phase III data from the trial are expected by the end of 2014. ADMA operates ADMA BioCenters, a revenue generating, FDA-licensed plasma collection organization which also provides a portion of the raw material for the Company’s lead product candidate, RI-002. ADMA shares begin trading on the Nasdaq Capital Market on November 10, 2014.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research